Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | The function of TAM receptors in health and disease

Greg Lemke • 18 Mar 2022
AD/PD 2022
Alzheimer’s Disease Dementia

Greg Lemke, PhD, Salk Institute for Biological Studies, San Diego, CA, outlines the function of TAM receptors (Tyro3, Axl, and Mer), expressed on the sentinel cells of the immune system, such as macrophages and dendritic cells. TAM receptors recognize phosphatidylserine expressed on apoptotic cells, subsequently leading to their removal by phagocytosis. TAM receptors also act as inhibitors of the immune response when activated on macrophages and dendritic cells at the end of the response. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.

More from Greg Lemke

Developments on microglia in neuroinflammation: TREM2 upregulation in Alzheimer’s disease
2:05
Developments on microglia in neuroinflammation: TREM2 upregulation in Alzheimer’s disease
Greg Lemke • 18 Mar 2022
Increasing the expression of Mer receptors in microglia: a potential therapy for Alzheimer’s disease
2:32
Increasing the expression of Mer receptors in microglia: a potential therapy for Alzheimer’s disease
Greg Lemke • 18 Mar 2022
Antibody-based therapy in Alzheimer's disease: future outlook
0:38
Antibody-based therapy in Alzheimer's disease: future outlook
Greg Lemke • 18 Mar 2022
Role of TAM receptors in Alzheimer’s disease
3:25
Role of TAM receptors in Alzheimer’s disease
Greg Lemke • 18 Mar 2022

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals